Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports a corporate governance event dated August 27, 2018. The report details the appointment of a new senior executive officer effective August 28, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details rather than financial performance.
Material Changes
The primary material change is the appointment of Christopher Boerner, Ph.D., as Executive Vice President and Chief Commercial Officer. Mr. Boerner previously served as the head of international markets and head of the U.S. commercial organization within the company.
Management Commentary and Compensation
Effective August 28, 2018, Mr. Boerner's compensation package includes:
- An annual base salary of $835,000.
- Eligibility for an annual incentive payout with a target opportunity of 100% of his base salary, subject to performance goals.
- Participation in the annual long-term incentive award program, including performance share units and market share units.
- Change-in-control and severance benefits consistent with other executive officers.
The filing states there are no family relationships between Mr. Boerner and any director or executive officer, and no related party transactions exist.
Investor Verification Checklist
- Verify the effective date of the appointment (August 28, 2018).
- Confirm the specific terms of the long-term incentive awards under the 2012 Stock Award and Incentive Plan.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the commercial organization.